<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium iodide and iodine (Lugol solution): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium iodide and iodine (Lugol solution): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium iodide and iodine (Lugol solution): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="13039" href="/d/html/13039.html" rel="external">see "Potassium iodide and iodine (Lugol solution): Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="15564" href="/d/html/15564.html" rel="external">see "Potassium iodide and iodine (Lugol solution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55195642"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lugols Strong Iodine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F802367"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseptic, Topical;</li>
<li>
                        Antithyroid Agent</li></ul></div>
<div class="block doa drugH1Div" id="F802397"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Lugol's 5% solution (potassium iodide 10% and iodine 5%) contains ~6.25 mg iodine/iodide per drop; 1 drop = 0.05 mL (ACR-SPR 2015; manufacturer's labeling). Errors have occurred involving iodine-containing solutions; verify the indication and intended solution concentration before administration (ISMP 2011).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92f24669-8855-4888-be89-8262b83630ab">Antiseptic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiseptic:</b> Topical: Apply directly to area(s) requiring antiseptic.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b71d9a92-75e1-4e23-b84e-4361a1e98524">Graves disease, thyroidectomy preparation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graves disease, thyroidectomy preparation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use is <b>not</b> recommended in patients with thyrotoxicosis caused by a toxic adenoma or toxic multinodular goiter due to the risk of exacerbating hyperthyroidism (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Lugol's 5% solution: 5 to 7 <b>drops</b> (0.25 to 0.35 mL) 3 times daily for 10 days before surgery (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antithyroid drug therapy (eg, methimazole) is started several weeks before surgery to achieve euthyroidism; if not euthyroid prior to surgery, or if urgent surgery is required, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (ATA [Ross 2016]; Burch 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="983b48df-1521-45eb-aacb-baab001e0e41">Thyroid gland protection during radiopharmaceutical use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid gland protection during radiopharmaceutical use (off-label use):</b>
<b>Note: </b>Regimens/protocols vary by radiopharmaceutical. Generally, ~100 mg/day of iodine/iodide is required for thyroid block (ACR-ACNM [Subramaniam 2017]; Anderson 2012; Taïeb 2012). Initiate 1 to 48 hours prior to radiopharmaceutical exposure and continue after radiopharmaceutical administration until risk of exposure has diminished (treatment initiation time and duration are dependent on the radiopharmaceutical agent used, consult specific protocol or labeling). The following product-specific recommendations are provided in the radiopharmaceutical manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:4em;">Iodine I-123 radiopharmaceuticals: <b>Oral: </b>Lugol’s 5% solution: 16 <b>drops</b>/day (0.8 mL/day) to achieve a dose of 100 mg/day of iodine/iodide (radiopharmaceutical manufacturer's labeling [Adreview, Datscan]).</p>
<p style="text-indent:-2em;margin-left:4em;">Iodine I-125 and I-131 radiopharmaceuticals: <b>Oral: </b>Lugol’s 5% solution: 10 <b>drops</b> (0.5 mL) 3 times daily (radiopharmaceutical manufacturer's labeling [Jeanatope, Megatope, Volumex]). The manufacturer's labeling for Azedra does not provide specific dosing recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm:</b>
<b>Note: </b>Administer at least 1 hour after antithyroid drug administration (eg, propylthiouracil, methimazole) (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Lugol's 5% solution: 4 to 10 <b>drops</b> (0.2 to 0.5 mL) every 6 to 8 hours (ATA [Ross 2016]; Nayak 2006; Ross 2022). May discontinue after evidence of clinical improvement (eg, defervescence, resolution of CNS and cardiovascular manifestations); for patients undergoing thyroidectomy within 10 to 14 days of initiating iodine therapy, may continue until day of surgery (ATA [Ross 2016]; Nayak 2006; Ross 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990187"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987561"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F803629"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F802396"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13039" href="/d/html/13039.html" rel="external">see "Potassium iodide and iodine (Lugol solution): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Errors have occurred during the prescribing, dispensing, and administration of iodine-containing solutions; verify the dosing units (eg, drops, mL) and intended solution concentration before administration (ISMP 2011). Doses may be presented as drops or mL; use caution and carefully verify dosage units before dispensing or administering.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Lugol's 5% solution (potassium iodide 10% and iodine 5%) contains ~6.25 mg iodine per drop; 1 drop = 0.05 mL (ACR-SPR 2015; Minamitani 2017; manufacturer's labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="576f3ec3-d7e5-4014-894e-a3b2f651e2bc">Thyrotoxic crisis/thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxic crisis/thyroid storm:</b> Limited data available: Children and Adolescents: Lugol's 5% solution: Oral: 4 to 10 <b>drops</b> (0.2 to 0.5 mL) 3 times daily; begin therapy preferably 1 hour following the initial dose of either propylthiouracil or methimazole (ETA [Mooij 2022]; Nichols 2008).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154213"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51154214"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F802379"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia, myxedema</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Confusion, fatigue, metallic taste, numbness, tingling sensation</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Goiter, hyperthyroidism, hypothyroidism</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea, enlargement of salivary glands, gastric distress, gastrointestinal hemorrhage, nausea, salivary gland disease (tenderness), stomach pain, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Adenopathy, thyroid adenoma</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Arthralgia, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pharyngeal edema</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Drug overdose (with prolonged treatment/high doses), fever, iodism</p></div>
<div class="block coi drugH1Div" id="F802375"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to iodine or any component of the formulation; tuberculosis (TB) disease (active TB); dermatitis herpetiformis; hypocomplementemic vasculitis; nodular thyroid disease with heart disease</p></div>
<div class="block war drugH1Div" id="F802376"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Prolonged use can lead to hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Can cause acne flare-ups and/or dermatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with Addison disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchitis: Use with caution in patients with acute bronchitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Use with caution in patients with cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myotonia congenita: Use with caution in patients with myotonia congenita.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with a history of hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: Use with caution in patients with tuberculosis.</p></div>
<div class="block dosfc drugH1Div" id="F51468656"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Lugol's 5% oral solution (potassium iodide 10% and iodine 5%) contains potassium iodide 100 mg/mL and iodine 50 mg/mL and provides 6.25 mg iodide/iodine per drop.</p></div>
<div class="block foc drugH1Div" id="F802404"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, External:</p>
<p style="text-indent:-2em;margin-left:4em;">Lugols Strong Iodine: Potassium iodide 10% and iodine 5% (8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Potassium iodide 10% and iodine 5% (8 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Potassium iodide 10% and iodine 5% (14 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Tincture, External:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Potassium iodide 5% and iodine 7% (30 mL, 480 mL)</p></div>
<div class="block geq drugH1Div" id="F802365"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adm drugH1Div" id="F16350658"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Apply topically directly to area(s) requiring antiseptic.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Dilute with water or juice. In patients with thyroid storm, administer at least 1 hour after antithyroid drug administration (eg, propylthiouracil, methimazole).</p></div>
<div class="block admp drugH1Div" id="F52614143"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Dilute with water or fruit juice.</p></div>
<div class="block use drugH1Div" id="F802370"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiseptic: </b>Topical antiseptic.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Graves disease, thyroidectomy preparation: </b>Treatment of hyperthyroidism in the immediate preoperative period in patients undergoing thyroidectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Iodine therapy is not recommended in the preoperative setting in patients with thyrotoxicosis caused by a toxic adenoma or toxic multinodular goiter due to the risk of exacerbating hyperthyroidism (ATA [Ross 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm: </b>Treatment of thyroid storm (as part of a multimodality treatment approach).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The American Thyroid Association and American Association of Clinical Endocrinologists guidelines for the management of hyperthyroidism and other causes of thyrotoxicosis recommend potassium iodide and iodine (Lugol's solution) as an acceptable alternative to saturated solution of potassium iodide (SSKI) in the management of adults with thyrotoxic crisis/thyroid storm (ATA [Ross 2016]).</p></div>
<div class="block off-label drugH1Div" id="F25744678"><span class="drugH1">Use: Off-Label: Adult</span><p>Thyroid gland protection during radiopharmaceutical use</p></div>
<div class="block mst drugH1Div" id="F802787"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Potassium iodide and iodine (Strong Iodide Solution or Lugol's solution) may be confused with potassium iodide products, including saturated solution of potassium iodide (SSKI)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dosage volume: Dosing errors have been reported during the prescribing, dispensing, and administration of potassium iodide-containing solutions (eg, Lugol's, SSKI). Errors have occurred when <b>mL</b> doses were administered, when only <b>drops</b> were indicated for the dose. Carefully review dosage and administration information; appropriate oral dosage is most commonly expressed as drops to provide doses less than 1 mL. Dispensing unit doses is also highly recommended; pharmacists should never dispense quantities that could be lethal if consumed as a single dose (ISMP 2011).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299923"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F802385"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antithyroid Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antithyroid agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Potassium Iodide may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue potassium iodide at least 3 weeks before sodium iodide I-131 administration, and avoid concurrent use.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Iodine may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue topical iodine at least 3 weeks before sodium iodide I-131 administration, and avoid concurrent use.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F802372"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Potassium iodide/iodine may be used in the management of thyroid storm or thyrotoxic heart failure in pregnant patients (ACOG 2020). Potassium iodide solution may be preferred for use in pregnant patients with hyperthyroidism who do not tolerate antithyroid medications in preparation for surgery (ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Sodium Iodide monograph for additional information related to systemic iodine and pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Iodine monograph for additional information related to topical iodine exposure and pregnancy.</p></div>
<div class="block brc drugH1Div" id="F802374"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iodine is present in breast milk; concentrations vary depending on maternal dietary intake (IOM 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to the Sodium Iodide monograph for additional information related to systemic iodine and pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to the Iodine monograph for additional information related to topical iodine exposure and pregnancy.</p></div>
<div class="block mop drugH1Div" id="F802398"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Thyroid function tests, signs/symptoms of hyperthyroidism; following radioiodine exposure, monitor thyroid function in pregnant patients, neonates, and young infants if repeat doses are required.</p></div>
<div class="block pha drugH1Div" id="F802391"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline">In hyperthyroidism, iodine temporarily inhibits thyroid hormone synthesis and secretion into the circulation; use also decreases thyroid gland  size and vascularity. Serum T<sub>4</sub>  and T<sub>3</sub> concentrations can be reduced for several weeks with use but effect will not be maintained.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Following radioactive iodine exposure, potassium iodide blocks uptake of radioiodine by the thyroid, reducing the risk of thyroid cancer.</p></div>
<div class="block phk drugH1Div" id="F802393"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hyperthyroidism: 24 to 48 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 10 to 15 days after continuous therapy</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58202470"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Iodine | Lodine tincture</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lugol | Pabron nodo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lugols</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lugol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ACR-SPR.1">
<a name="ACR-SPR.1"></a>ACR-SPR Practice parameter for the performance of tumor scintigraphy (with gamma cameras). Revised 2015. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/tumorscint.pdf. Accessed May 14, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AdreView.1">
<a name="AdreView.1"></a>AdreView (iobenguane I-123 injection) [prescribing information]. Arlington Heights, IL: GE Healthcare Medi-Physics Inc; March 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. <i>Thyroid</i>. 2017;27(3):315-389. doi:10.1089/thy.2016.0457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443080">
<a name="32443080"></a>American College of Obstetricians and Gynecologist (ACOG). ACOG Practice Bulletin No 223: Thyroid disease in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/32443080/pubmed" id="32443080" target="_blank">32443080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22302091">
<a name="22302091"></a>Anderson EA. Correction of an important typographical error in the European Association of Nuclear Medicine (EANM) guidelines. <i>Eur J Nucl Med Mol Imaging</i>. 2012;39(6):1080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/22302091/pubmed" id="22302091" target="_blank">22302091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bexxar.1">
<a name="Bexxar.1"></a>Bexxar (tositumomab and iodine I 131 tositumomab) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26670972">
<a name="26670972"></a>Burch HB, Cooper DS. Management of Graves disease: a review. <i>JAMA</i>. 2015;314(23):2544-2554. doi:10.1001/jama.2015.16535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/26670972/pubmed" id="26670972" target="_blank">26670972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cherella.1">
<a name="Cherella.1"></a>Cherella CE, Wassner AJ. Thyroid disorders. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022: chap. 61.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Datscan.1">
<a name="Datscan.1"></a>Datscan (ioflupane I-123 injection) [prescribing information]. Arlington Heights, IL: GE Healthcare Medi-Physics Inc; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Deladoey.1">
<a name="Deladoey.1"></a>Deladoey J, von Oettingen JE, Van Vliet G. Disorders of the thyroid in the newborn and infant. In: Sperling MA, ed. <i>Pediatric Endocrinology</i>. 5th ed. Elsevier; 2020:chap. 8.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18274745">
<a name="18274745"></a>Giammarile F, Chiti A, Lassmann M, Brans B, Flux G; EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. <i>Eur J Nucl Med Mol Imaging</i>. 2008;35(5):1039-1047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/18274745/pubmed" id="18274745" target="_blank">18274745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strong.1">
<a name="Strong.1"></a>Humco Strong Iodine Solution USP (iodine and potassium iodide) [prescribing information]. Texarkana, TX: Humco Holding Group, Inc.; November 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP), “Look out for Lugol’s...Error-prevention strategies for this strong iodine solution,” ISMP Medication Safety Alert, December 1, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academy Press; 2001. https://doi.org/10.17226/10026.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jeanatope.1">
<a name="Jeanatope.1"></a>Jeanatope (iodinated I-125 injection) [prescribing information]. Friendswood, TX: Iso-Tex Diagnostics, Inc; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strong.2">
<a name="Strong.2"></a>Lugol's Strong Iodine Solution USP (iodine and potassium iodide) [prescribing information]. Trumbull, CT: Cooper Surgical.; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Megatope.1">
<a name="Megatope.1"></a>Megatope (iodinated I-131 albumin injection) [prescribing information]. Friendswood, TX: Iso-Tex Diagnostics, Inc; April 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28458457">
<a name="28458457"></a>Minamitani K, Sato H, Ohye H, Harada S, Arisaka O, Committee on Pharmaceutical Affairs, Japanese Society for Pediatric Endocrinology, and the Pediatric Thyroid Disease Committee, Japan Thyroid Association (Taskforce for the Revision of the Guidelines for the Treatment of Childhood-Onset Graves’ Disease). Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016. <i>Clin Pediatr Endocrinol</i>. 2017;26(2):29-62. doi:10.1297/cpe.26.29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/28458457/pubmed" id="28458457" target="_blank">28458457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34981748">
<a name="34981748"></a>Mooij CF, Cheetham TD, Verburg FA, et al. 2022 European Thyroid Association guideline for the management of pediatric Graves' disease. <i>Eur Thyroid J</i>. 2022;11(1):e210073. doi:10.1530/ETJ-21-0073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/34981748/pubmed" id="34981748" target="_blank">34981748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127140">
<a name="17127140"></a>Nayak B, Burman K. Thyrotoxicosis and Thyroid Storm. <i>Endocrinol Metab Clin North Am</i>. 2006;35(4):663-686, vii.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/17127140/pubmed" id="17127140" target="_blank">17127140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nichols.1">
<a name="Nichols.1"></a>Nichols DG, ed. <i>Roger's Textbook of Pediatric Intensive Care</i>. 4th ed. Lippincott, Williams &amp; Wilkins; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Thyroid storm. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strong.3">
<a name="Strong.3"></a>Strong iodine solution (iodine and potassium iodide) [prescribing information]. Texarkana, TX: Humco Holding Group Inc; November 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28922189">
<a name="28922189"></a>Subramaniam RM, Frey KA, Hunt CH, Mercier GA Jr, Solnes LB, Colletti PM, Lu Y, Savir-Baruch B, Williams HT. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. <i>Clin Nucl Med</i>. 2017;42(11):847-852. doi:10.1097/RLU.0000000000001815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/28922189/pubmed" id="28922189" target="_blank">28922189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926712">
<a name="22926712"></a>Taïeb D, Timmers HJ, Hindié E, et al; European Association of Nuclear Medicine. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>Eur J Nucl Med Mol Imaging</i>. 2012;39(12):1977-1995. doi:10.1007/s00259-012-2215-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/22926712/pubmed" id="22926712" target="_blank">22926712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Volumex.1">
<a name="Volumex.1"></a>Volumex (iodinated I-131 albumin injection) [prescribing information]. Friendswood, TX: Iso-Tex Diagnostics Inc; April 2014.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9455 Version 133.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
